Dr. Weiping Liu 刘卫平
Chief Physician, Associate Professor
Department of Lymphoma, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lymphomas, including Hodgkin, non-Hodgkin, B-cell, T-cell, and Castleman disease. Expertise in hematopoietic stem cell transplantation, CAR-T therapy, targeted therapy, and immunotherapy.
Dr. Liu holds a medical doctorate and serves as Chief Physician and Associate Professor. Dr. Liu is the Deputy Director of the Transplantation and Immunotherapy Ward at Peking University Cancer Hospital.
Professional roles
- Member, Chinese Medical Association
- Vice Chair, Youth Committee of the Lymphoma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Secretary-General, Autologous Hematopoietic Stem Cell Transplantation Working Group, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member and Secretary-General, Lymphoma Branch, China Health Education Association
Name order: in Chinese the family name comes first (Liu Weiping). Papers usually list the name as Weiping Liu or Liu W.
Selected publications
115 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- Am J Hematol, 2026 (senior author): Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study. PubMed 42360011
- Chin J Cancer Res, 2026 (first author): Updates of CSCO guidelines for diagnosis and treatment of lymphoma: 2026 edition. PubMed 42421897
- Ann Hematol, 2026 (senior author): Global burden of non-Hodgkin lymphoma in the elderly: a population-based study using GBD 2021. PubMed 41557002
- Front Pediatr, 2025 (senior author): Global burden of Hodgkin lymphoma among children and adolescents: a population-based study using GBD 2021. PubMed 41357793
- MedComm (2020), 2025 (senior author): Genetic Subtype-Based International Prognostic Index Prognostic Model in Diffuse Large B-Cell Lymphoma. PubMed 40529616
- Heliyon, 2024 (senior author): National and subnational mortality trends of multiple myeloma in China, 2013-2020: Empirical evidence from national mortality. PubMed 39021914
- Signal Transduct Target Ther, 2023 (first author): Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. PubMed 37726266
- Cancer Med, 2023 (senior author): Different situations of identifying second primary malignant tumors in lymphoma patients with synchronous solid tumors. PubMed 36621802
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion